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Background: Changes in genomic copy number occur in many human diseases including cancer.
Characterization of these changes is important for both basic understanding and diagnosis of these
diseases. Microarrays have recently become the standard technique and are commercially available.
However, it is useful to have an affordable technique to complement them.
Results:  We describe a novel polymerase chain reaction (PCR)-based technique, termed
competitive genomic PCR (CGP). The main characteristic of CGP is that different adaptors are
added to the sample and control genomic DNAs after appropriate restriction enzyme digestion.
These adaptor-supplemented DNAs are subjected to competitive PCR using an adaptor-primer
and a locus-specific primer. The amplified products are then separated according to size differences
between the adaptors. CGP eliminates the tedious steps inherent in quantitative PCR and achieves
moderate throughput. Assays with different X chromosome numbers showed that it can provide
accurate quantification. High-resolution analysis of neuroblastoma cell lines around the MYCN
locus revealed novel junctions for amplification, which were not detected by a commercial array.
Conclusion: CGP is a moderate throughput technique for analyzing changes in genomic copy
numbers. Because CGP can measure any genomic locus using PCR primers, it is especially useful
for detailed analysis of a genomic region of interest.
Background
Variations in DNA copy number occur in many diseases
such as Down, Prader-Willi, Turner and Angelman syn-
dromes, as well as in cancer. In particular, a loss or gain of
DNA copy number is frequently observed in cancer, affect-
ing (respectively) tumor suppressor genes and oncogenes.
Techniques that detect abnormalities in DNA copy
number are therefore useful for studying the associations
between DNA aberrations and disease phenotype and for
locating critical genes.
Comparative genomic hybridization (CGH) was devel-
oped for genome-wide analysis of DNA copy number and
is based on two-color fluorescence in situ hybridization
(FISH) [1]. In CGH, differentially-labeled total genomic
DNAs from a 'test' and a 'reference' cell population are co-
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hybridized to normal metaphase chromosomes, using
blocking DNA to suppress signals from repetitive
sequences. The resulting fluorescence intensity ratio at a
location on the 'cytogenetic map' of the chromosomes is
approximately proportional to the ratio of copy numbers
between the corresponding DNA sequences in the test and
reference genomes. However, the use of metaphase chro-
mosomes limits the detection of events involving small
regions (less than 20 Mb) of the genome, i.e. the resolu-
tion of closely spaced aberrations, making it difficult to
assign their genomic locus. Moreover, CGH results must
be adjusted for biases in the correlation of the hetero-
scedastic data distribution in a two-color FISH [2],
although use of the "dye swap" method substantially
reduces this problem.
Recently, a DNA microarray-based CGH was developed
[3-5]. In addition, oligonucleotide arrays for detecting
SNP have been used to analyze genomic copy numbers
[6]. These microarray-based methods have higher resolu-
tion than FISH-based CGH, and the recent availability of
commercial products has increased the popularity of this
technique. However, because currently available arrays
have gaps between probes, some regions are not available
for analysis. It is important to have a technique for mak-
ing detailed measurements of DNA copy number in
regions of interest.
In this report, we describe a new technique for measuring
changes in gene copy number to meet these needs.
Polymerase chain reaction (PCR) is an alternative tech-
nique for quantifying genome copy number. Although
several reports have used PCR to measure DNA copy num-
bers [7-9], it has not gained broad popularity because
careful calibration is required for accurate quantification.
In the new PCR-based technique described here, compet-
itive genomic PCR (CGP), competitive PCR is performed
using restricted genomic DNA ligated to specific adaptors
as a template. Different adaptors are added to the test and
control samples and the test-to-reference ratio is deter-
mined by quantifying the amplified products fractionated
by gel electrophoresis. CGP does not require preliminary
calibration experiments, considerably improving the
throughput and rapidity of the experimental process. This
technique complements hybridization-based techniques
for CGH and can easily serve as an alternative to FISH or
array-based CGH, especially for high-resolution analysis
of a particular chromosome region.
Results
Outline of the CGP assay
The CGP assay comprises several enzymatic steps to pro-
duce a PCR template containing genomic DNA ligated to
specific adaptors. A scheme of the method is presented in
Fig. 1. First, double-strand genomic DNA was digested
with the restriction endonuclease Pstl, which cleaves at
CTGCAG. The first 5'-biotinylated adaptor (PT1) was then
ligated to DNA sample A, the adaptor (PT2) to sample B
and the third (PT3) to sample C (Fig. 1). The three adap-
tors shared a common sequence and had a cohesive end
complementary to the PstI restriction site; however, the
second adaptor was 3 bases longer than the first and the
third was 3 bases longer than the second (these extra bases
were located between the common sequence and the
overhang). After ligation, we mixed the three DNA sam-
ples; the first and the third adaptors were both ligated
with Fmix DNA as a reference (see Materials and Meth-
ods), but in different quantities (one equivalent or one
half equivalent, respectively), while the second was used
for the test sample (one equivalent). The samples were
digested with the restriction endonuclease MboI, which
recognizes the 4 bp cleavage site GATC. Adaptor-supple-
mented genomic DNA fragments were recovered using
streptavidin-coated paramagnetic beads and were PCR-
amplified using an adaptor-specific and a locus-specific
primer complementary to a sequence near the PstI recog-
nition site. MboI digestion and subsequent purification
by the beads removes most of genomic DNA, which may
result in artifactual amplification. For detection, the adap-
tor-primer was labeled with a fluorescent dye. The ampli-
fied fragments were separated by denaturing
polyacrylamide gel electrophoresis and quantified with an
automated sequencer.
Using this procedure, we tested the CGP assay using Fmix
and Mmix DNAs (see Materials and Methods) as refer-
ences for 132 loci on chromosome X and 60 loci on chro-
mosome 17. When we used Fmix DNA for both the test
and reference samples, the test/reference fluorescence
ratios measured for loci on chromosome X were tightly
distributed around a log2 value of 0 (Fig. 2A). In contrast,
when we compared genomic DNA from Mmix (46, XY)
with Fmix (46, XX), the distribution of fluorescence ratios
for chromosome X loci was shifted and approached a
mean log2 value of -1, while the ratios for loci on chromo-
some 17 remained at a log2 value of 0. These differences
reflect the absence of the single-copy chromosome X from
the control male samples (Fig. 2B). The standard devia-
tion of the log2 values was 0.27 excluding outliers, and
0.31 including outliers.
Design of locus-specific primers for the CGP assay
In the CGP assay, it is important that each primer binds to
a single locus in the genome. In addition, because CGP is
used to study genetic changes in cancer, the loci used for
quantification should be located near genes that are com-
monly expressed in cancer tissues. To fulfill these require-
ments we adopted the following strategy.BMC Genomics 2007, 8:206 http://www.biomedcentral.com/1471-2164/8/206
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Outline of the CGP assay Figure 1
Outline of the CGP assay. Schematic representation of the CGP assay for quantification using PstI and MboI as restriction 
enzymes.
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A, B. Validation of the CGP assay using Fmix vs. Fmix (A), or Fmix vs. Mmix (B) Figure 2
A, B. Validation of the CGP assay using Fmix vs. Fmix (A), or Fmix vs. Mmix (B). The horizontal axis displays 132 loci of chro-
mosome X and 60 loci of chromosome 17. The vertical axis represents test/reference log2 fluorescence ratio of each locus. C, 
D. Sensitivity of CGP for detecting a change in low-level copy number. CGP was performed to determine the copy number of 
loci in the chromosome X. Fmix DNA (46, XX) was used as a reference DNA for all reactions. The distribution of test/refer-
ence fluorescence ratios for the different test samples of chromosome X DNA (C). Vertical axis, the percentage of DNAs; 
horizontal axis, test/reference fluorescence ratio. The doublet line, bold line, solid line, dotted line and dashed line indicate the 
Mmix/Fmix, Fmix/Fmix, 47, XXX/Fmix, 48, XXXX/Fmix and 49, XXXXX/Fmix fluorescence ratios, respectively. The mean rel-
ative ratios of autosomal DNAs (dotted line) and chromosome X DNA (solid line) from each experiment versus the number 
of X chromosomes (D). Mean (± 1 s.d.) fluorescence ratios of chromosome X DNA were as follows; XY versus XX, 0.69 
(0.49–0.89); XX versus XX, 1.00 (0.84–1.15); XXX versus XX, 1.37 (1.10–1.64); XXXX versus XX, 1.62 (1.21–2.02); XXXXX 
versus XX, 2.08 (1.63–2.52). A dotted line for chromosome X and a solid line for autosomal mean fluorescence ratios were fit-
ted using standard regression analysis.
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We previously performed gene expression profiling on
more than a thousand cancer tissues by adaptor-tagged
competitive PCR (ATAC-PCR) [10-14] for the Cancer
Gene Expression Database (CGED) [15,16]. For each can-
cer type we performed middle-scale EST sequencing (the
number of tags usually exceeded 5,000), and selected
genes for assay among the expressed genes. It should be
noted that our ESTs correspond to an mRNA region with
an MboI site closest to the 3' end. The number of ESTs
sequenced to date is 18,042. We used this EST collection
to construct the CGP primer library.
The procedure for designing the locus-specific primers is
presented schematically in Fig. 3. First, all the ESTs in the
collections were compared with the human genome by a
BLAST search of the NCBI database [17]. When an EST
matched a single chromosomal locus, we isolated it
together with the surrounding 10 kbp of genomic DNA.
Second, we searched for PstI restriction sites in the region
surrounding the MboI site of the EST. We designed prim-
ers that were 15–65 bases downstream or upstream from
the PstI site and had a melting temperature between 56
and 64°C. Using the dbSNP database [18], we eliminated
primer sequences or PstI sites containing SNPs and prim-
ers in which a MboI restriction site was present between
the PstI site and the locus-specific primer sequence.
Finally, the primers were screened using a BLAST search in
Ensembl [19]; we selected only those that matched a sin-
gle chromosomal locus. The primer sequences for the
whole genome are supplied as the additional data file 1.
Detection of changes in low-level DNA copy number
To test the sensitivity of CGP in detecting changes in sin-
gle copy numbers, we used genomic DNA from cell lines
with varying numbers of X chromosomes (to simulate dis-
tinct levels of gene amplification and deletion) and com-
pared 132 loci of chromosome X with 60 loci of
chromosome 17.
When we compared two Fmix samples used as both test
and reference DNA, the test/reference fluorescence ratios
measured for chromosome X loci were tightly distributed
around a mean value of 1 (Fig. 2C). In contrast, when we
compared genomic DNA from Mmix (46, XY) with Fmix
(46, XX), the distribution of fluorescence ratios for chro-
mosome X loci was shifted to a mean value of 0.69
(expected 0.5; Fig. 2C, D). Similarly, when we compared
genomic DNAs from 47, XXX 48, XXXX and 49, XXXXX
cell lines using Fmix DNA, the distribution of fluorescence
ratios for chromosome X loci was shifted to mean log2 val-
ues of 1.37, 1.62 and 2.08, respectively (expected 1.5, 2.0,
2.5; Fig. 2C, D), reflecting the increase in chromosome X
DNA copy-number. The mean fluorescence ratios for
chromosome X loci obtained in the different experiments
displayed a tight linear fit (Fig. 2D), with a correlation
coefficient of 0.996. This demonstrates that the fluores-
cence ratios were linearly proportional to DNA copy
number even with a low-level gene-amplification or sin-
gle-copy deletion.
Detection of v-myc myelocytomatosis viral-related 
oncogene (MYCN) amplification and analysis of the 
chromosome breakpoints
To characterize the ability of CGP to measure differences
in copy number in genomic DNA, we evaluated regional
amplification in neuroblastoma-derived cell lines.
Neuroblastoma is one of the most common pediatric
solid tumors and accounts for 7–10% of all childhood
cancers. The prognosis of patients varies according to
stage, age and MYCN  amplification status. The MYCN
oncogene (located at 2p24.3) is particularly important.
Since it was first described in 1983 [20] it has served a fun-
damental prognostic role for neuroblastoma patients.
MYCN amplification has been detected in more than 80%
of neuroblastoma cell lines [21], whereas other regions
with high-level genomic amplification have rarely been
observed. We verified MYCN amplification in ten neurob-
lastoma cell lines by Southern hybridization. This gene
was amplified in all ten cell lines except SH-SY5Y and
NBL-S (Fig. 4A).
Outline of locus-specific primer design Figure 3
Outline of locus-specific primer design. 'M' and 'P' indicate 
the MboI and PstI restriction sites, respectively.
GATC AAAAAAAAA
1) Retrieval of chromosomal locus matched the EST sequence  by Blast search
M
genomic DNA
2) Search for the nearest Pst I site from  MboI site of EST
M P
EST sequence
(mRNA)
3) Design of the primers from Pst I site to fit defined conditions
P
4) Final selection of primer by Blast Search 
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Detection of MYCN gene amplification in neuroblastoma cell lines in CGP Figure 4
Detection of MYCN gene amplification in neuroblastoma cell lines in CGP. A. Confirmation of MYCN amplification in neurob-
lastoma cell lines by Southern hybridization. B. CGP analysis of neuroblastoma cell lines. DNA copy number profiles for chro-
mosome region 2p25.3-2q14.3 (approximately every 1.3 Mbps) containing the MYCN gene were derived from 96 
oligonucleotide primers. All 12 neuroblastoma-derived cell lines were examined, but only the SH-SY5Y, TNB-1, NGP and SK-
N-BE lines are displayed. Horizontal axis indicates each locus from 2pter (bp), and vertical axis shows test/reference log2 fluo-
rescence ratio. The MYCN loci are indicated by black circles. C. CGP high-resolution analysis (approximately every 48 kbps) in 
neuroblastoma cell lines. DNA copy number profiles for chromosome 2p24.2-2p24.3 containing the MYCN gene were derived 
from 72 oligonucleotide primers and represented 66 loci. All 12 neuroblastoma-derived cell lines were examined, but only 
NBL-S, SK-N-DZ, TGW and RTBM1 cell lines are displayed. Horizontal axis indicates each locus from 2pter, and vertical axis 
shows test/reference log2 fluorescence ratio. The arrow and black circles denote the MYCN loci. D. Summary of the amplified 
region surrounding the MYCN gene. The vertical axis indicates the amplified loci between 15.5 Mega (M) bp and 17.5 M bp from 
2pter. The black bars denote the DNA amplification sites for each cell line. Regions where amplifications were detected in 
more than 2 spots of the CGP assay were defined as "amplification sites". The dashed line represents the loci of NAG, DDX1, 
MYCN and FAM49A.
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Initially, the CGP assay was performed on all the neurob-
lastoma cell lines using 96 primers located approximately
every 1.3 Mbps, spanning 2p25.3 to 2q14.3 and contain-
ing the MYCN gene. In all the lines except SH-SY5Y and
NBL-S, CGP detected the amplified MYCN gene (Fig. 4B)
in agreement with the Southern blot analysis. Focusing on
the region adjacent to the MYCN gene locus, we generated
72 primers approximately every 48 kbps between 2p24.3
and 2p24.2. These primer sequences are supplied as the
additional data file 2. Each cell line except SH-SY5Y and
NBL-S had an amplified region that was detected by the
CGP assay. For instance, NBL-S cells showed no amplifi-
cation in this region, whereas amplification was observed
at 2p24.3 in SK-N-DZ and RTBM1 (15,501,688-
16,300,557 bp from the short arm telomeric end (2pter)
of chromosome 2 and 15,890,708-16,320,323 bp from
2pter, respectively), including amplification of the MYCN
gene (Fig. 4C). MYCN amplification was detected in the
TGW cell line, but it was accompanied by discontinuities
between the top of the MYCN gene and the middle of
2p24.2 (16,032,021 bp and 17,263,397 bp from 2pter).
The amplified region in the vicinity of the MYCN gene is
summarized in Fig. 4D. Only the neuroblastoma-ampli-
fied gene (NAG), DEAD (Asp-Glu-Ala-Asp) box polypep-
tide 1 (DDX1),  MYCN  and hypothetical protein
LOC81553 (FAM49A) are present in this region between
15.5 × 106 bp and 17.5 × 106 bp from 2pter [22]. NAG and
DDX1 are reported to be co-amplified with the MYCN
gene in neuroblastoma [23], but amplification of DDX1
and/or NAG has no additional adverse effect on prognosis
in this disease [24,25].
Comparing CGP to an oligonucleotide array
To compare CGP with microarrays, we used both meth-
ods to measure DNA copy numbers on chromosome 2 in
TGW cells. We chose the Affymetrix GeneChip 50K Hind
array, which has a mean marker distance of 50 kb and has
a resolution equal to the previous CGP experiments (Fig.
4C). An intensely amplified region was observed on the
short arm of chromosome 2 (Fig. 5A, B). However, addi-
tional DNA aberrations were detected only by CGP (Fig.
4C, TGW). In addition, no specific amplification of the
MYCN gene was detected by the Affymetrix array because
of a lack of probes in the MYCN region.
Discussion
In this study we describe a novel PCR-based method for
detecting changes in genomic DNA copy number.
Although techniques have been described that use liga-
tion of synthetic oligonucleotides for genomic amplifica-
tion and RNA quantification, CGP is the first to use them
for quantifying genomic DNA [26]. In the CGP assay we
used the PstI restriction enzyme, which recognizes the 6
bp sequence CTGCAG, to fractionate the DNA. The high
prevalence of PstI sites in genomic DNA offers a mapping
resolution of approximately 46 = 4096 bps, which is sig-
nificantly greater than FISH-based CGH (~20 Mb). PstI
could be substituted by another enzyme such as SacI, Hin-
dIII or XhoI (which are unaffected by DNA modification)
if no PstI sites are present near the gene of interest.
CGP is capable of detecting small copy number differ-
ences such as XX versus XY, XXX, XXXX or XXXXX. The
mean relative ratio values for chromosome X loci were
0.69 for XY/XX, 1.0 for XX/XX, 1.37 for XXX/XX, 1.62 for
XXXX/XX and 2.08 for XXXXX/XX, as shown in Fig. 2D.
These data are comparable to those obtained with array
based-CGH [3,4].
As a model for the study of gene amplification in human
cancer, we focused on MYCN  gene copy alterations in
neuroblastoma-derived cell lines. We used the CGP assay
to detect gene amplification in each cell line at approxi-
mately every 1.3 Mbps in the vicinity of the MYCN gene,
and observed MYCN gene amplification in all but two of
the lines, SH-SY5Y and NBL-S. Furthermore, examination
of the region adjacent to the MYCN gene locus at approx-
imately every 48 kbps revealed that these cell lines had a
diversity of small region amplifications between 15.5 ×
106 bp and 17.5 × 106 bp from 2pter (Fig. 4D). A recently
updated gene assembly database showed that NAG,
DDX1, MYCN and FAM49A map to this same region on
chromosome 2. These genes have previously been shown
to be amplified in cancer, but it is also possible to use CGP
to focus on or identify additional genes involved in cancer
or other diseases.
Owing to its robustness, PCR offers a reliable alternative
to DNA hybridization-based techniques. For example,
quantitative PCR is routinely used to confirm results
obtained by DNA microarrays. Thus, although the current
versions of microarray-based techniques are sound, it is
desirable to have an alternative PCR-based technique to
confirm the results. Real-time PCR has been used for this
purpose but tedious calibration experiments make it diffi-
cult to use for high-throughput applications [8]. In CGH,
two genomic sources are labeled with two different fluo-
rescent dyes and hybridized in a single reaction vessel.
Because these labeled DNAs are competitively hybridized
to chromosomal DNA or spotted BAC DNA, the ratio of
the two dyes indicates quantitative differences in the par-
ticular locus of the genome. In CGP, two DNA sources are
differentiated after competitive PCR by the size of the
adaptors. In principle, both techniques use a competitive
reaction between two different genomic DNA sources. As
indicated by experiments with various numbers of X chro-
mosomes, the CGP technique provided the desirable level
of quantification. It should be noted that both techniques
are limited in dynamic range: for example, the dynamic
range of CGP would be up to about 20-fold as estimatedBMC Genomics 2007, 8:206 http://www.biomedcentral.com/1471-2164/8/206
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Detection of MYCN gene amplification in TGW cell line using oligonucelotide arrays Figure 5
Detection of MYCN gene amplification in TGW cell line using oligonucelotide arrays. A. DNA copy number changes on chro-
mosome 2. The horizontal axis indicates each locus from 2pter to 2qter, and the vertical axis shows estimated copy number. 
Gains or losses in DNA copy number are indicated by the blue and red bars, respectively. The brown box depicts the amplified 
region in chromosome 2 and is expanded in B. B. The region adjacent to the MYCN gene locus highlights chromosomal 
changes (the brown box region in Fig.5A). The Integrated Genome Browser (IGB) was used for visualization of the data. The 
horizontal axis indicates chromosome locus, and the vertical axis shows estimated copy number. The two red lines indicate 
15.5 M bp and 17.5 M bp, respectively, as in Fig. 4D.
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from the results of adaptor-tagged competitive PCR [27],
a similar technique for quantifying RNA.
CGP lends itself to applications in several specific cases.
Because the throughput of the technique is moderate, it is
easy to profile chromosomal gains or losses at the resolu-
tion of conventional CGH. Microarrays would be the
method of choice for profiling the entire genome, and
CGP may be used to complement it. In this study, CGP
detected DNA discontinuities that were not found with a
microarray. This suggests that commercial arrays may miss
chromosomal alterations because of gaps between probes.
If a particular chromosomal region is important for a
piece of research, more data points should be added, and
CGP can be a useful tool for such purposes. The main
merit of CGP is the ease with which any locus in the
human (or other) genome may be analyzed simply by
making a single PCR primer. As shown by the example of
MYCN in neuroblastoma, high-resolution mapping of a
particular genome locus is one of the major applications
of CGP. Such high-resolution mapping can be achieved
with less cost and effort than hybridization-based tech-
niques. In addition, the robustness of PCR would be
advantageous in cases with limited DNA sources such as
those obtained by laser micro-beam dissection, a promis-
ing technique for cancer research.
The above applications of CGP are for research purposes.
In the near future, it will be important to analyze the loss
or gain of chromosomal loci for diagnosis. In such cases,
CGP will be a rapid and accurate method and a strong
candidate for clinical applications.
Conclusion
CGP is a moderate throughput PCR-based technique for
analyzing changes in genomic copy number. Because CGP
can measure any genomic locus just by supplying PCR
primers, it is especially useful for detailed analysis of a
genomic region of interest at a higher resolution than
commercial CGH arrays.
Methods
Genomic DNA
Blood samples were obtained from 10 healthy male and
10 female Japanese volunteers with informed consent.
Equal quantities of genomic DNA were prepared from
each blood sample as previously described [28] and the
samples from each gender were mixed (Mmix or Fmix) to
avoid variations in genomic copy number in the control
samples [29,30]. Genomic DNAs from human cell lines
were also used. Genomic DNAs from the following cell
lines were obtained from the Coriell Cell Repository for
Medical Research (Camden, NJ, USA): 47, XXX (reposi-
tory no. NA04626), 48, XXXX (repository no. NA01416),
and 49, XXXXX (repository no. NA06061). Genomic
DNAs from neuroblastoma-derived cell lines (SH-SY5Y,
NBL-S, NGP, CHP134, SMS-SAN, SK-N-BE, SK-N-DZ,
TGW, LA-N-5, RTBM1, TNB-1 and GOTO) were obtained
from the Chiba Cancer Center Research Institute (Chiba,
Japan). For each reaction (locus) of the CGP assay, 1 ng of
each genomic DNA test sample was used.
Design of PCR primers and adaptors
To measure the genome copy number, locus-specific
primers were designed. There were 132 primers for chro-
mosome X, 60 primers for chromosome 17 and 96 prim-
ers for chromosome 2, all of which were 20-mer
oligonucleotides. The primers consisted of 18 bases of
genomic DNA sequence from a region that was 15–65
bases upstream or downstream of a PstI site, and GT
nucleotides were added to the 5' end of each primer so
that Taq DNA polymerase would add an "A" to the end of
Table 1: Sequences of adaptors and the adaptor primer.
Name Oligomer Sequences
PT adaptors
PT1
bPT1L 5'-biotin-GTACATATTGTCGTTAGAACGCGTCAATCCATACTTGCA-3'
PT1S 5'-AGTATGGATTGACGCGTTCTAACGACAATATGTAC-3'
PT2
bPT2L 5'-biotin-GTACATATTGTCGTTAGAACGCGTACTCAATCCATACTTGCA-3'
PT2S 5'-AGTATGGATTGAGTACGCGTTCTAACGACAATATGTAC-3'
PT3
bPT3L 5'-biotin-GTACATATTGTCGTTAGAACGCGCTATACTCAATCCATACTTGCA-3'
PT3S 5'-AGTATGGATTGAGTATAGCGCGTTCTAACGACAATATGTAC-3'
Adaptor primer
C1S-FAM 5'-6FAM -GTACATATTGTCGTTAGAACGC-3'
Each adaptor consists of a pair of oligomers designated S and L. The three adaptors shared a common sequence (bold) and had a cohesive end 
complementary to the PstI restriction site (underlined). Biotin was added to the 5' ends of the longer oligomers for the subsequent purification 
step, and 6FAM was used to label the C1S adaptor primer, which was complementary to the shared sequence of the three adaptors.BMC Genomics 2007, 8:206 http://www.biomedcentral.com/1471-2164/8/206
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the strand extending from the adaptor primer [31]. Addi-
tion of GT allows us to omit the trimming step by T4 DNA
polymerase before measuring the quantity of fragments.
All primers used in this study were custom-made by
Hokkaido System Science (Hokkaido, Japan). The
sequences of the adaptors (designated PT1 to PT3) and
the fluorescent dye-labeled adaptor primer are shown in
Table 1. The size differences between the adaptors were
three bases, the minimum distance required for complete
separation of adjacent peaks. 6-Carboxyfluorescein (FAM)
was used to label the adaptor primer.
CGP assay and data processing
In the CGP assay, 1 μg of each genomic DNA was treated
with 15U of the restriction enzyme PstI (TaKaRa, Kyoto,
Japan) in a 20 μl reaction volume. The enzyme was inac-
tivated at 70°C for 20 min, then 7.6 pmol of a 5'-bioti-
nylated adaptor (PT1, PT2 or PT3 adaptor) was added to
a 4 μl aliquot of the PstI-digested DNA (test or reference)
in a 10 μl volume containing 1 × ligation buffer and 3U
T4 DNA ligase (Promega, Madison, USA), and incubated
at 16°C for more than 12 hours. After the enzyme has
been heat-inactivated at 70°C for 20 min, the three
genomic DNA samples were mixed as follows: 4 μl PT1, 4
μl PT2 and 2 μl PT3. The DNA mixture was purified twice
on silica gel columns (QIAGEN GmbH, Germany) to
remove enzymes, salt and short fragments such as unli-
gated adaptors. The final 50 μl volume of DNA was treated
with 20U of the restriction enzyme MboI (TaKaRa, Kyoto,
Japan) in a 100 μl reaction mixture at 37°C for 20 min,
followed by the addition of 25 μl 5 M NaCl. Fifty micro-
liters of streptavidin-coated paramagnetic beads (1 mg/
ml, Dynal Biotech, USA), which were initially washed
with 50 μl of 1 × B&W buffer [10 mM TrisHCl (pH 7.5), 1
M NaCl and 1 mM EDTA], were added to the mixture,
incubated for 20 min at room temperature, then washed
three times with distilled water (DW) to remove the
genomic DNA fragments cleaved by MboI. DW was added
to adjust the volume to 200 μl. Each set of PCR premix-
tures consisted of 110 μl 10 × PCR buffer, 13.2 μl 20 mM
dNTP mixture, 1320 pmol C1S-FAM primer and 150U
AmpliTaq Gold (Applied Biosystems, CA USA) in a final
volume of 800 μl. For a single round of PCR reactions,
200 μl of the master DNA template mixture was com-
bined with 800 μl of the PCR premixture, and a 9 μl aliq-
uot of this solution was added to each well of a 96-well
microtiter plate. One microliter of each 10 pmol/μl locus-
specific primer solution was then added to each well. The
PCR cycling program was as follows: 95°C for 10 min fol-
lowed by five cycles of 94°C for 30 s, 65°C for 30 s and
72°C for 45 s; a second set of five cycles of 94°C for 30 s,
60°C for 30 s and 72°C for 45 s; a third set of 10 cycles of
94°C for 30 s, 55°C for 30 s and 72°C for 45 s; and finally
30 cycles of 94°C for 30 s, 50°C for 30 s and 72°C for 45
s, followed by 72°C for 30 min. The PCR products were
loaded and separated by the automated sequencer ABI
3730 (Applied Biosystems, CA USA), and the fluorescent
intensity of each peak was recorded. We applied a single
sample in one capillary, and the running time of electro-
phoresis was less than 30 minutes: we processed more
than 1,000 samples per day.
The shortest and longest adaptors (PT1 and PT3) were
used for control references (Fmix DNA) in equivalents of
one and of one half, respectively, while the medium-
length adaptor (PT2) was used for the test sample in one
equivalent (Fig. 1). Therefore, the expected DNA copy
number in the test sample was:
Test/reference fluorescence ratio = 2xPT2/(xPT1+2xPT3)
Here, xPT1, xPT2 or xPT3 are the heights of the peaks contain-
ing locus-specific DNA ligated to PT1, PT2 or PT3, respec-
tively (Fig. 1). If the raw peak height of PT1 was lower
than 1,000 in fluorescence intensity, the data were omit-
ted.
Southern hybridization to detect MYCN amplification
Five micrograms of high molecular weight genomic DNA
prepared from various neuroblastoma-derived cell lines
were digested completely with EcoRI, size-fractionated on
1% agarose gels, transferred to nylon membrane filters
and immobilized by UV irradiation. The hybridization
probe was prepared from gel-purified MYCN cDNA frag-
ments, which were radio-labeled with [α-32P] dCTP by the
random-priming procedure. Hybridization was per-
formed overnight at 65°C in a solution containing 1 M
NaCl, 1% N-lauroyl sarcosine, 7.5% dextran sulfate, 100
μg/ml heat-denatured salmon sperm DNA and the radi-
olabeled probe DNA. After hybridization, the membrane
filters were washed twice with 2 × SSC/0.1% N-lauroyl sar-
cosine at room temperature followed by one wash with
0.1 × SSC/0.1% N-lauroyl sarcosine at 65°C and exposed
to X-ray film with an intensifying screen at -70°C.
Oligonucleotide array analysis
The Affymetrix Gene Chip Human Mapping 50 K Hind
Array (Santa Clara, CA) was used for all experiments fol-
lowing the GeneChip Mapping 50 K protocols. Fmix DNA
served as a control. The Affymetrix Chromosome Copy
Number Anaylysis Tool (CNAT) 4.0 was used for the data
analysis.
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